Dr. Xiaolong Qi is a distinguished medical professional with expertise in liver health, portal hypertension, and cirrhosis. He serves as a Professor of Medicine at Zhongda Hospital, Southeast University, Nanjing, China, and holds several key leadership positions in the medical community. Dr. Qi is the Founder and Chair of the Liver Health Consortium in China (CHESS), as well as the Founding Editor-in-Chief of Portal Hypertension & Cirrhosis (PH&C). His research contributions are internationally recognized, and he has received numerous honors and awards for his outstanding work in the field.
Author Metrics:
Dr. Qi’s impact as an author is reflected in his author metrics, including citation count, h-index, and other indicators of scholarly influence. His publications have garnered attention within the scientific community, contributing to advancements in hepatology and related fields.
Scopus Profile
Orcid Profile
Xiaolong Qi is affiliated with Zhongda Hospital, Southeast University, located in Nanjing, China. His Scopus Author Identifier is 55753297300. He has an ORCID profile with the identifier 0000-0002-3559-5855. Qi has a significant academic footprint with 8,364 citations from 7,338 documents, indicating the impact and reach of his research. He has authored 225 documents, resulting in an h-index of 44, showcasing his influential contributions to the scientific community.
Education:
Dr. Qi earned his Bachelor of Medicine from Tongji University, Shanghai, China, in 2013. He furthered his medical education by pursuing a Medical Doctor degree at Tongji University from 2013 to 2015, during which he engaged in clinical observations at Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Research Focus:
Dr. Qi’s research primarily focuses on liver health, portal hypertension, and cirrhosis. He explores various aspects of these conditions, including their pathophysiology, diagnostic methods, treatment strategies, and epidemiology. His work aims to advance understanding and improve clinical management for patients suffering from these complex disorders.
Professional Journey:
Dr. Qi’s professional journey spans across prestigious institutions in China and the United States. He has held positions as a Senior Research Fellow at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, and as an Associate Professor at Southern Medical University, Guangzhou, China. Throughout his career, Dr. Qi has demonstrated a commitment to research, education, and clinical practice in the field of hepatology.
Honors & Awards:
Dr. Qi has received several honors and awards in recognition of his significant contributions to the medical community. These accolades highlight his excellence in research, leadership, and academic achievements, further establishing him as a key opinion leader in his field.
Publications Top Noted & Contributions:
Dr. Qi has made substantial contributions to scientific literature through his publications and academic endeavors. He has authored numerous research papers, reviews, and book chapters in prominent journals and publications, enriching the understanding of liver diseases and portal hypertension. Additionally, his editorial roles and participation in advisory boards underscore his influence in shaping medical discourse and research priorities.
Carvedilol to prevent decompensation of liver cirrhosis in patients with clinically significant portal hypertension stratified by novel non-invasive model
- Date: 2023-09-12
- Type: Preprint
- DOI: 10.22541/au.169450109.98248913/v1
- Contributors: Xiaolong Qi, Chuan Liu, Hong You, Qing-Lei Zeng, Wong YJ, Bingqiong Wang, Ivica Grgurevic, Bingtian Dong, Wei Gou, Shenghong Ju, et al.
- Source: Crossref
Metaâanalysis of the immunogenicity of standard and booster SARSâCoVâ2 vaccination in patients with chronic liver disease and postâliver transplantation
- Date: 2023-06
- Type: Journal article
- DOI: 10.1002/poh2.49
- Contributors: WenâXin Wang, Jitao Wang, Rui Jia, Silvia Martini, Jiaye Liu, Yifei Huang, FuâSheng Wang, Xiaolong Qi, Junliang Fu
- Source: Portal Hypertension & Cirrhosis via Crossref
Correspondence on Editorial regarding âBaveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patientsâ
- Date: 2023-01-01
- Type: Journal article
- DOI: 10.3350/cmh.2022.0408
- Contributors: Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani
- Source: Clinical and Molecular Hepatology via Crossref
A strategy for varices screening based on acoustic radiation force impulse combined with platelet (CHESS2001): An alternative of Baveno VI criteria
- Date: 2022-11
- Type: Journal article
- DOI: 10.1002/hep4.2076
- Contributors: Yifei Huang, Lili Zhao, Ruiling He, Shuang Li, Chuan Liu, Xiaolong Qi, Jia Li
- Source: Hepatology Communications via Crossref
Research Timeline:
Dr. Qi’s research timeline illustrates his progressive trajectory in academia and research. From his early education to his current professorship, he has consistently pursued excellence in scholarship and scientific inquiry, leaving a lasting impact on the understanding and management of liver diseases and portal hypertension.
